204 related articles for article (PubMed ID: 15961648)
1. American Society of Gene Therapy meeting. Retroviral vectors: a double-edged sword.
Kaiser J
Science; 2005 Jun; 308(5729):1735-6. PubMed ID: 15961648
[No Abstract] [Full Text] [Related]
2. The leukemogenic risk of integrating retroviral vectors in hematopoietic stem cell gene therapy applications.
Kang EM; Tisdale JF
Curr Hematol Rep; 2004 Jul; 3(4):274-81. PubMed ID: 15217557
[TBL] [Abstract][Full Text] [Related]
3. Gene therapy of chronic granulomatous disease (CGD) by gene transfer into hematopoietic stem cells.
Zentilin L; Tafuro S; Serra C; Falaschi A; Giacca M
Ann Ist Super Sanita; 1998; 34(4):447-55. PubMed ID: 10234875
[TBL] [Abstract][Full Text] [Related]
4. Gene therapy. Second child in French trial is found to have leukemia.
Marshall E
Science; 2003 Jan; 299(5605):320. PubMed ID: 12531981
[No Abstract] [Full Text] [Related]
5. Regulators split on gene therapy as patient shows signs of cancer.
Check E
Nature; 2002 Oct; 419(6907):545-6. PubMed ID: 12374936
[No Abstract] [Full Text] [Related]
6. Is retroviral gene marking too dangerous to use?
Brenner MK; Heslop HE
Cytotherapy; 2003; 5(3):190-3. PubMed ID: 12850996
[No Abstract] [Full Text] [Related]
7. Genes can come true.
Phillips H
New Sci; 2002 Nov; 176(2371):30-3. PubMed ID: 12731520
[No Abstract] [Full Text] [Related]
8. Medicine. Gene therapy--new challenges ahead.
Williams DA; Baum C
Science; 2003 Oct; 302(5644):400-1. PubMed ID: 14563994
[TBL] [Abstract][Full Text] [Related]
9. Genotoxicity of retroviral integration in hematopoietic cells.
Nienhuis AW; Dunbar CE; Sorrentino BP
Mol Ther; 2006 Jun; 13(6):1031-49. PubMed ID: 16624621
[TBL] [Abstract][Full Text] [Related]
10. Progress towards hematopoietic stem cell gene therapy.
Kurre P; Kiem HP
Curr Opin Mol Ther; 2000 Aug; 2(4):400-11. PubMed ID: 11249770
[TBL] [Abstract][Full Text] [Related]
11. US panel advises resumption of gene trials.
Fox JL
Nat Biotechnol; 2002 Nov; 20(11):1068-9. PubMed ID: 12410240
[No Abstract] [Full Text] [Related]
12. Transgene optimization significantly improves SIN vector titers, gp91phox expression and reconstitution of superoxide production in X-CGD cells.
Moreno-Carranza B; Gentsch M; Stein S; Schambach A; Santilli G; Rudolf E; Ryser MF; Haria S; Thrasher AJ; Baum C; Brenner S; Grez M
Gene Ther; 2009 Jan; 16(1):111-8. PubMed ID: 18784749
[TBL] [Abstract][Full Text] [Related]
13. Gene therapy. What to do when clear success comes with an unclear risk?
Marshall E
Science; 2002 Oct; 298(5593):510-1. PubMed ID: 12386304
[No Abstract] [Full Text] [Related]
14. Gene therapy. Panel urges limits on X-SCID trials.
Kaiser J
Science; 2005 Mar; 307(5715):1544-5. PubMed ID: 15761128
[No Abstract] [Full Text] [Related]
15. Enhancer-deleted retroviral vectors restore high levels of superoxide generation in a mouse model of CGD.
Schwickerath O; Brouns G; Thrasher A; Kinnon C; Roes J; Casimir C
J Gene Med; 2004 Jun; 6(6):603-15. PubMed ID: 15170731
[TBL] [Abstract][Full Text] [Related]
16. Gene therapy. RAC hears a plea for resuming trials, despite cancer risk.
Kaiser J
Science; 2003 Feb; 299(5609):991. PubMed ID: 12586909
[No Abstract] [Full Text] [Related]
17. Gene therapy. Seeking the cause of induced leukemias in X-SCID trial.
Kaiser J
Science; 2003 Jan; 299(5606):495. PubMed ID: 12543948
[No Abstract] [Full Text] [Related]
18. Gene therapy resumes.
Novak K
Nat Rev Cancer; 2002 Nov; 2(11):813. PubMed ID: 12442759
[No Abstract] [Full Text] [Related]
19. Looking into the safety of AAV vectors.
Kay MA; Nakai H
Nature; 2003 Jul; 424(6946):251. PubMed ID: 12867952
[No Abstract] [Full Text] [Related]
20. Gene therapy. RAC's advice: proceed with caution.
Kaiser J
Science; 2002 Dec; 298(5601):2113-5. PubMed ID: 12481114
[No Abstract] [Full Text] [Related]
[Next] [New Search]
